Loading clinical trials...
Loading clinical trials...
A Phase 1 Dose Escalation With Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMV564 Alone and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Conditions
Interventions
AMV564
Locations
11
United States
UCLA
Los Angeles, California, United States
Advent Health
Orlando, Florida, United States
Moffitt Cancer Center
Tampa, Florida, United States
Northwestern University
Chicago, Illinois, United States
Duke University Medical Center
Durham, North Carolina, United States
The Christ Hospital
Cincinnati, Ohio, United States
Start Date
October 9, 2019
Primary Completion Date
December 15, 2021
Completion Date
December 31, 2021
Last Updated
October 19, 2021
NCT06716138
NCT06307795
NCT05581004
NCT06974812
NCT06107686
NCT05205109
Lead Sponsor
Amphivena Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions